What's the most commercially mature microbial glycolipid today?

Sophorolipid, by a wide margin. S. bombicola naturally produces at 150+ g/L, gravity phase separation DSP is industrially proven (Holiferm, Givaudan, Evonik), and sub-$10/kg COGS is achievable with current technology. Sophorolipid is in commercial production for industrial cleaners, agricultural adjuvants, and some personal-care formulations today. Rhamnolipid is mature for industrial cleaners and niche applications but COGS is still $12-25/kg for most producers. MEL is the newest to the industrial market with Kao Corporation leading on cosmetic applications at premium pricing.

Why does each glycolipid need a different DSP approach?

Sophorolipid aggregates into a dense immiscible phase at high concentration in low-water broth, so gravity phase separation works. Rhamnolipid is a strong surfactant that foams aggressively in the broth, so foam fractionation is the efficient DSP. MEL stays emulsified and requires solvent extraction for recovery. These are consequences of the molecular structures: sophorolipid has a bulky sugar head that drives it out of aqueous phase at high concentration, rhamnolipid is a classic amphiphile optimized for interface adsorption (foam), and MEL has intermediate surface properties that require an active solvent to pull it out.

Can one producer realistically make all three glycolipids, or is each a separate process?

Each is a separate process with a different organism, different fermentation conditions, different DSP train. A facility could run multiple glycolipid products on shared upstream equipment (fermentors, utilities) with dedicated DSP per product, but operating three products simultaneously creates complexity that most producers avoid. Commercial strategy is usually to pick one glycolipid and scale it, with the other two as future options. Holiferm focuses on sophorolipid. Evoleaf/Glycosurf on sophorolipid. Kao/Ceramela on MEL. Jeneil/Stepan on rhamnolipid.

Which glycolipid is best for cosmetic applications specifically?

MEL is preferred for high-end cosmetics because of its exceptional skin-friendly properties (moisturizing, anti-irritant, near-neutral pH in formulation). Sophorolipid is in growing use for mid-range cosmetics and personal care. Rhamnolipid is generally considered too harsh for cosmetics unless heavily diluted or formulated specifically to buffer its pH. Product specifications for cosmetics typically require additional DSP polishing regardless of which glycolipid, because the base spec is much tighter than for industrial cleaners.

How does Augur handle all three in one platform?

Each has its own built-in organism profile (S. bombicola for sophorolipid, P. putida for rhamnolipid, M. aphidis for MEL) with appropriate default kinetics, feedstock mixes, temperature and pH ranges. The DSP templates differ: phase_separation for sophorolipid, foam_fractionation for rhamnolipid, solvent_extraction for MEL. Users can override any parameter and swap DSP steps to compare routes (e.g., what if we used solvent extraction for sophorolipid? What if we tried foam fractionation for MEL?). Direct scenario comparison lets a team pick the right category for their application and constraints.

MEL vs sophorolipid vs rhamnolipid: which glycolipid fits which application

Microbial glycolipids are the most commercially advanced category of biosurfactants, and three products dominate: sophorolipids from Starmerella bombicola, rhamnolipids from engineered Pseudomonas putida, and MEL (mannosylerythritol lipid) from Moesziomyces aphidis. These three categories have very different production economics, physical properties, and regulatory paths. This post compares them head-to-head and maps which fits which application so a team evaluating biosurfactant entry can choose with open eyes.

Production economics

All values below are typical for industrial-scale production (20,000-50,000 L) with optimized strains and mature DSP.

Metric	Sophorolipid	Rhamnolipid	MEL
Host organism	S. bombicola (yeast)	P. putida (engineered)	M. aphidis (yeast)
Typical titer	120-180 g/L	30-50 g/L	35-50 g/L
High-titer strains	200-400 g/L	60-80 g/L	55-80 g/L
Fermentation time	200-300 h	80-120 h	120-240 h
Primary DSP	Gravity phase separation	Foam fractionation	Solvent extraction
DSP yield	75-85%	65-75%	70-80%
Typical COGS	$8-24/kg	$18-35/kg	$40-100/kg
State-of-art COGS	$2.50-5/kg	$8-14/kg	$25-45/kg

Sophorolipid has a structural cost advantage: much higher titer, much cheaper DSP. Rhamnolipid sits in the middle with foam fractionation closing part of the titer gap. MEL is expensive by comparison because the organism is slower, titer is lower, and solvent extraction DSP is both more capital-intensive and more operationally demanding.

Physical and surface properties

Property	Sophorolipid	Rhamnolipid	MEL
CMC (critical micelle concentration)	~30-80 mg/L	~10-40 mg/L	~3-10 mg/L
Surface tension reduction	~33 mN/m	~27 mN/m	~28 mN/m
HLB (hydrophilic-lipophilic balance)	10-13	22-25	8-12
Preferred pH range	Acidic (pH 4-6)	Neutral to alkaline	Wide (pH 3-9)
Skin-compatibility	Moderate-to-good	Can be irritant	Excellent
Biodegradability	Excellent	Excellent	Excellent

MEL's very low CMC (often below 10 mg/L) means you use dramatically less to achieve the same surfactant effect. That partially offsets the cost disadvantage: if your formulation needs 3 g/L of rhamnolipid but only 0.5 g/L of MEL for equivalent performance, the higher per-kg price becomes less dramatic on a per-product-unit basis. This matters for cosmetic and personal-care applications where finished-product cost per unit matters more than cost per kg of surfactant.

Regulatory paths

Sophorolipid: GRAS status in the US for some applications. EU and several Asian markets have approved it for cosmetic and cleaning applications. Straightforward path for most non-food uses.
Rhamnolipid: Approved for industrial, agricultural, and cleaning applications globally. Cosmetic approval is jurisdictionally variable. Food and pharmaceutical applications are much more restricted because engineered P. putidahost requires endotoxin and host-cell-protein clearance documentation.
MEL: Approved for cosmetics in Japan, EU, and most developed markets. Food applications are under evaluation in several regions. Industrial cleaner application is established. Because M. aphidis is non-pathogenic and the product is wild-type, the regulatory path is cleaner than for engineered hosts.

Application mapping

Industrial cleaners and degreasers

Winner: rhamnolipid or sophorolipid depending on cost target. For price-sensitive commodity cleaning (bulk degreaser, floor cleaner), sophorolipid at $8-15/kg beats rhamnolipid at $18-28/kg. For performance-sensitive applications (specialty solvents, niche industrial), rhamnolipid's lower CMC and neutral pH make it the default choice.

Agricultural adjuvants

Winner: rhamnolipid. The surfactant properties and biodegradability make it ideal for spreader-stickers and pesticide formulation adjuvants. Sophorolipid is a reasonable second choice. MEL is rarely used in agriculture because the cost-to-performance ratio doesn't justify it.

Personal care (shampoo, body wash, liquid soap)

Winner: sophorolipid. It has the best combination of cost, skin compatibility, and foaming performance for mid-range personal care. MEL is better for skin but too expensive for mass-market. Rhamnolipid is generally avoided because its pH profile doesn't formulate cleanly.

High-end cosmetics (serums, moisturizers, anti-aging)

Winner: MEL. The skin-compatibility and low CMC make it formulation-friendly at very low inclusion rates (0.1-0.5%), so the premium price is hidden in the finished-product cost structure. Kao Corporation's Ceramela line is the reference industrial example.

Enhanced oil recovery (EOR)

Winner: rhamnolipid. Works well at high salinity, stable at moderate temperature, biodegradable. Commercial EOR applications have been running for a decade using rhamnolipid.

Food and nutraceutical applications

Winner: MEL or sophorolipid depending on jurisdiction. Wild-type organism origin and clean regulatory path favor these over engineered-host rhamnolipid. Approved food applications are narrow but growing, mostly as emulsifiers in specialty food products.

Scale-up considerations by category

Scale-up risk profile differs:

Sophorolipid: main risk is kLa crash under high viscosity. Mitigation is well-understood. Most scale-ups hit projected titer within 15-25% at 20,000 L.
Rhamnolipid: main risk is foam management at scale. Foam fractionation eliminates this if the DSP is designed around it. Without foam fractionation, antifoam-based scale-ups often miss titer by 30-50% at 20,000 L.
MEL: main risk is solvent extraction economics and purification complexity. Scale-up on fermentation side is manageable (kLa, mixing are adequate). DSP scale-up requires capital-intensive solvent recovery loops that make first-batch production capital costs high.

What Augur models

All three organisms are built-in profiles with appropriate default kinetics. The three canonical DSP routes (phase separation, foam fractionation, solvent extraction) are registered unit operations that can be swapped between scenarios. A team evaluating which glycolipid to pursue can run three side-by-side scenarios with the same target scale, same facility sharing assumption, same batch cadence, and directly compare predicted titer, yield, DSP performance, and COGS.

The platform also flags strain-specific warnings: foam fractionation for sophorolipid has low enrichment (it's flagged as suboptimal), solvent extraction for rhamnolipid consumes significantly more solvent than foam fractionation would (flagged as higher-cost route), phase separation for MEL doesn't work at industrial concentration (flagged as inappropriate). This keeps scenario comparisons anchored to realistic process combinations rather than arbitrary swaps that wouldn't work in practice.

If you're evaluating which glycolipid category fits your application and want to see side-by-side scale-up predictions,request access. Pilot customers typically run 3-5 scenario comparisons across organisms before committing to a development path.